Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report issued on Tuesday, October 8th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings of $0.09 per share for the year, down from their prior estimate of $0.14. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q4 2025 earnings at $0.24 EPS.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million.

Several other research analysts have also recently commented on ESPR. Needham & Company LLC reduced their target price on Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating for the company in a research report on Tuesday, August 13th. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. StockNews.com raised shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, October 5th. Finally, Bank of America cut Esperion Therapeutics from a "neutral" rating to an "underperform" rating and decreased their price target for the company from $2.90 to $2.50 in a report on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $8.17.

Esperion Therapeutics Stock Down 2.1 %

ESPR stock traded down $0.04 during trading hours on Thursday, hitting $1.89. The company's stock had a trading volume of 3,327,045 shares, compared to its average volume of 6,422,102. The company has a market capitalization of $358.08 million, a PE ratio of -1.88 and a beta of 1.00. The stock has a 50 day moving average price of $1.83 and a two-hundred day moving average price of $2.19. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40.

Institutional Investors Weigh In On Esperion Therapeutics

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC grew its stake in shares of Esperion Therapeutics by 105.9% during the third quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company's stock worth $127,000 after buying an additional 39,635 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Esperion Therapeutics by 104.8% in the second quarter. Mackenzie Financial Corp now owns 35,254 shares of the biopharmaceutical company's stock worth $78,000 after acquiring an additional 18,036 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in Esperion Therapeutics during the 2nd quarter valued at $159,000. Deerfield Management Company L.P. Series C acquired a new position in Esperion Therapeutics during the 2nd quarter valued at about $148,000. Finally, Marshall Wace LLP grew its holdings in Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock worth $9,554,000 after buying an additional 2,087,635 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.